AUTO-3

N/A

Report date: 2025/07/15 20:00:07

Base Information

Drug NameAUTO-3

Drug Alias NameAUTO-3

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > γ-retroviral vectorCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionAnti-CD19Anti-CD22

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity College London

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAutolus Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A